HSU weights from studies identified in SLR

|  |  |  |  |
| --- | --- | --- | --- |
| **Author (Year)** | **HRQL Elicitation &scoring** | **Groups** | **Utility, Mean (SD) n** |
| Blakeman (2014) | EQ-5DTTO Assume Dolan UK weights | CKD Stage 3 (Placebo) at baselineCKD Stage 3 (Placebo) at 6 months | 0.67 (0.30)0.67 (0.29) |
| Briggs (2016) | EQ-5D-3LTTODolan UK weights | *Myocardial infarction*Short term effectLong term effect*Hospitalisation for unstable angina*Short term effectLong term effect*Heart failure*Short term effectLong term effect*Peripheral vascular event*Short term effectLong term effect*Stroke*Short term effectLong term effect*Bone fracture*Short term effectLong term effect*Parathyroidectomy*Short term effectLong term effect | Disutilities:-0.12-0.10-0.11-0.05-0.11-0.10-0.31-0.20-0.20-0.11-0.31-0.12-0.060.01 |
| Davison (2008) | HUI-2Assumed standard HUI methods (VAS & SG)Canadian public | Pre-dialysis (n=116)Dialysis (n=62) | 0.78 (0.17)0.68 (0.22) |
| Davison (2009) | SF-6DAssume standard SF-6D methods (SG)Assume UK general public | Pre-dialysis (n=116)Dialysis (n=62) | 0.69 (0.13)0.62 (0.13) |
| Gorodetskaya (2005) | HUI-3Assumed standard HUI-3 methods (VAS & SG)Assumed Canadian public | GFR>=6030<=GFR<6015<=GFR<30GFR<15, NDGFR<15, dialysisDialysisLong term follow up stage 4/5 ptsUtility change  | 0.67 (0.31) n=220.67 (0.31) n=500.55 (0.34) n=650.54 (0.35) n=280.54 (0.33) n=660.54 (0.31) n=38-0.039 per year |
| Jardine (2017) | EQ-5D-3LNR | Standard haemodialysis: 12-18 hours per weekextended hemodialysis:24+ hours per week | 0.76 (0.25) n=1000.79 (0.23) n=100 |
| Jesky (2016) | EQ-5D-3LDolan 1997 UK TTO weights  | Stage G1/G2: normalStage G3a: GFR 45-59 (mild reduction)Stage G3b: GFR 30-44 (moderate/severe)Stage G4: GFR 15-29 (severe reduction)Stage G5: GFR<15 (kidney failure) | 0.85 (0.70, 1.0) n=290.80 (0.69, 1.0) n=450.80 (0.68, 1.0) n=1730.74 (0.62, 0.85) n=4230.73 (0.62, 1.0) n=75 |
| Lee (2005) | EQ-5D-3LDolan 1997 UK TTO weights  | Peritoneal dialysisHaemodialysisPre-dialysisRenal Transplant | 0.53 (0.34) n=740.44 (0.32) n=950.57 (0.33) n=330.71 (0.27) n=204 |
| Manns (2002) | EQ-5D-3LDolan 1997 UK TTO weights  | Kt/V<1.3Kt/V>=1.3All patients  | 0.450.650.60 95%CI (0.55, 0.64) |
| Manns (2003) | EQ-5D-3LDolan 1997 UK TTO weights  | HD Baseline HD after 12 monthsPD baselinePD after 12 months | Mean (std Error)0.65 (0.027)0.62 (0.030)0.64 (0.063)0.67 (0.046) |
| Manns (2009) | EQ-5D-3LDolan 1997 UK TTO weights  | Haemodialysis patients, baseline | Mean (95%CI)0.69 (0.63, 0.76) n=51 |
| Neri (2011) | EQ-5D-3LShaw, et al. USA TTO weights | Post-transplant CKD stage 1-2: GFR>60Post-transplant CKD stage 3: GFR 59-30Post-transplant CKD stage 4: GFR 29-15Post-transplant CKD stage 5: GFR <15 | 0.88 (0.15) n=1430.87 (0.14) n=1720.87 (0.10) n=510.82 (0.12) n=19 |
| Ortega (2007) | EQ-5D-3LTTO weights, possibly Spanish, report is ambiguous | Pre-transplant (ESRD)3 months post-transplant6 months post-transplant12 months post-transplant | 0.74 (0.21)0.81 (0.19)1.0 (0)0.82 (0.20) |
| Ortega (2009) | EQ-5D-3LTTO weights, possibly Spanish, report is ambiguous | Pre-transplantation <60yrsPre-transplantation > 60yrsPost transplantation <60yrsPost transplantation >60yrs | 0.610.780.740.86 |
| Ortega (2013) | SF-6DUK standard gamble weights | Graft clinical evaluation: Very good - goodAverage - bad | 0.78 n=1700.61 n=24 |
| Pan (2018) | SF-6D Hong Kong population weights, standard gamble | Total sample | 0.75 (0.11) n=315 |
| Wong (2019)a | SF-6D Hong Kong population weights, standard gamble | Peritoneal dialysisHospital haemodialysisHome haemodialysisCommunity haemodialysis | 0.78 (0.11) n=1030.73 (0.11) n=1350.78 (0.09) n=410.79 (0.11) n=118 |
| Abbreviations: CKD, chronic kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HRQOL, health-related quality of life; HUI, Health Utilities Index; NR, not reported; SD, standard deviation; SF-6D, Short Form questionnaire-6 Dimensions; SG, standard gamble; TTO, time trade-off ; VAS, visual analogue scale |